For US Health Care Professionals Only

The GILENYA Patient Services Liaison

A dedicated GILENYA Patient Services Liaison supports you, your staff, and your patients.*
The Liaison—a key component of the GILENYA Support Team—is the primary contact for you and your patients. The main goal of the program is to get your patients started on GILENYA.  More>
A dedicated GILENYA Patient Services Liaison
The baseline assessments and/or FDO for GILENYA can now be conducted in the comfort of patients’ own homes, by the GILENYA@Home medical team.*
  • Just submit an SRF and we take care of the rest
  • The service is covered at no additional cost to eligible patients with commercial insurance
  • Visits are arranged at times convenient to your patient
  • Patient Services Letters
    Use these form letters to appeal a denial of coverage or preauthorization, or to document the medical necessity of GILENYA for your patients.
    GILENYA Assessment Network Locator
    The GILENYA Assessment Network (GAN) has become an integral component of patient care and provides support for initiation of GILENYA. The GAN has extensive experience, performing more than 5,000 FDOs in over 320 sites across the United States. Novartis also offers in-home FDO for patients, which can be arranged with the help of a GILENYA Patient Services Liaison.
    GILENYA ECG Access Program: CardioNet
    CardioNet is available to assist with ECG interpretation and communications during each first-dose observation with GILENYA. If your office requires support, CardioNet can provide an ECG monitor and train your staff. CardioNet technicians prepare the ECG report and send it to a Harvard cardiologist to be overread. Each report is made available through CardioNet’s Web portal.
    *Eye exams are available @Home in select markets. Patients using Medicare, Medicaid, TRICARE or patients who reside in Massachusetts or Rhode Island are not eligible for services sponsored by Novartis. Other limitations apply.
    References: 1. Gilenya [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; October 2018. 2. Kappos L, Radue E-W, O’Connor P, et al; for FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. 3. Cohen JA, Barkhof F, Comi G, et al; for TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415. 4. Data on file. Summary of Clinical Efficacy in Multiple Sclerosis. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2009. 5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology. 1983;33(11):1444-1452. 6. Data on file. CSR 2302. Novartis Pharmaceuticals Corp; East Hanover, NJ. July 2009. 7. Data on file. CSR 2301. Novartis Pharmaceuticals Corp; East Hanover, NJ. July 2009. 8. Ge Y. Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol. 2006;27(6):1165-1176. 9. Hauser SL, Goodin DS. Multiple sclerosis and other demyelinating diseases. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: The McGraw-Hill Companies, Inc; 2008:2611-2621. 10. Data on file. Briefing document. Novartis Pharmaceuticals Corp; East Hanover, NJ. May 2010. 11. Data on file. GILENYA exposure: August 2018 cutoff. Novartis Pharmaceuticals Corp; September 2018. 12. Data on file. Hub SRF and Sales Table. Novartis Pharmaceuticals Corp. Q4 2017. 13. Data on file. CSR 2309. Novartis Pharmaceuticals Corp; East Hanover, NJ. July 2009. 14. Chun J, Hartung H-P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91-101. 15. Takabe K, Paugh SW, Milstien S, Spiegel S. “Inside out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60(2):181-195. 16. Data on file. GILENYA exposure: August 2018 cutoff. Novartis Pharmaceuticals Corp; September 2018. 17. DiMarco JP, O’Connor P, Cohen JA, et al. First-dose effects of fingolimod: pooled safety data from three phase 3 studies. Mult Relat Disord. 2014;3(5):629-638. 18. Degaute JP, van de Borne P, Linkowski P, et al. Quantitative analysis of the 24-hour blood pressure and heart rate patterns in young men. Hypertension. 1991;18(2):199-210. 19. Zdanowicz MM, Lynch LM. Teaching the pharmacology of antiarrhythmic drugs. Am J Pharm Educ. 2011;75(7):139. 20. Ganusov VV, De Boer RJ. Do most lymphocytes in humans reside in the gut? Trends Immunol. 2007;28(12):514-518. 21. Zhang ZQ, Notemans DQ, Sedgewick G, et al. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95(3):1154-1159. 22. Haynes BF, Soderberg KA, Fauci AS. Introduction to the immune system. In: Fauci AS, ed. Harrison’s Rheumatology. 2nd edition. New York, NY: The McGraw-Hill Companies; 2010:2-43. 23. Aubagio [prescribing information]. Cambridge, MA: Genzyme Corp; November 2016.